Peptide therapeutics for rare genetic metabolic diseases


Rhythm (NASDAQ: RYTM) is a biopharmaceutical company focused on developing peptide therapeutics for the treatment of rare genetic deficiencies that result in life‑threatening metabolic disorders. Rhythm’s lead peptide product candidate is setmelanotide, a first‑in‑class melanocortin‑4 receptor, or MC4R, agonist for the treatment of rare genetic disorders of obesity.


Year Invested: 2010
Location: Boston, Mass.
Visit: www.rhythmtx.com

Recent News

November 14, 2017
Rhythm Pharmaceuticals Reports Third Quarter 2017 Financial Results

October 31, 2017
Rhythm Announces Preliminary Data from Phase 2 Study of Setmelanotide for Treatment of Bardet-Biedl Syndrome

October 10, 2017
Rhythm Pharmaceuticals, Inc. Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Read More News

Associated Team Members

Neil Exter
Partner